Announcements Trials

Browse Landscape

Phase

Phase 2 53 Phase NA 13 Phase 2/3 6 Phase 4 5 Phase 3 5 Phase 1 3 Phase EARLY_PHASE1 2 Phase 1/2 1

Status

Sponsor Class

INDUSTRY 10 OTHER_GOV 1 OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 320 Leukemia, Myeloid, Acute 266 Multiple Myeloma 227 Carcinoma, Non-Small-Cell Lung 224 Prostatic Neoplasms 202 Neoplasms 196 Lymphoma 191 Colorectal Neoplasms 184 Melanoma 179 Leukemia 170 Recurrence 164 Pancreatic Neoplasms 163 Precursor Cell Lymphoblastic Leukemia-Lymphoma 160 Lung Neoplasms 150 Glioblastoma 134 Neoplasm Metastasis 132 Lymphoma, Non-Hodgkin 128 Ovarian Neoplasms 123 Leukemia, Lymphocytic, Chronic, B-Cell 120 Myelodysplastic Syndromes 117 Lymphoma, Large B-Cell, Diffuse 110 Lymphoma, Mantle-Cell 108 Carcinoma, Hepatocellular 103 Lymphoma, Follicular 99 Stomach Neoplasms 96 Carcinoma, Renal Cell 89 Hodgkin Disease 88 Brain Neoplasms 88 Sarcoma 84 Burkitt Lymphoma 75

Interventions

nimotuzumab 1 Afatinib 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1/2 × OTHER × NSCLC × Clear all

NCT01861223 2014-02-25

Afatinib Plus Nimotuzumb for NSCLC

Samsung Medical Center

Phase 1/2 Unknown

NSCLC

Data powered by HemOnc (CC BY 4.0) Colophon ⚡